Contineum Therapeutics (CTNM) Share-based Compensation (2023 - 2026)

Contineum Therapeutics' Share-based Compensation history runs 4 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 48.81% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $10.2 million (up 27.0% YoY), while the FY2025 annual figure was $10.0 million, up 47.53% from the prior year.
• Share-based Compensation was $3.8 million for Q1 2026 at Contineum Therapeutics, up from $2.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $3.8 million in Q1 2026 to a low of $300000.0 in Q2 2023.
• Historically, Share-based Compensation has averaged $1.6 million across 4 years, with a median of $1.3 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 663.67% in 2024, then gained 10.26% in 2025.
• A 4-year view of Share-based Compensation shows it stood at $759000.0 in 2023, then soared by 196.57% to $2.3 million in 2024, then grew by 10.26% to $2.5 million in 2025, then surged by 54.03% to $3.8 million in 2026.
• The last three Share-based Compensation figures came in at $3.8 million (Q1 2026), $2.5 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.